Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled …

K Nakagawa, EB Garon, T Seto, M Nishio… - The Lancet …, 2019 - thelancet.com
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
被引用次数：527 相关文章
[PDF] core.ac.uk

[PDF][PDF] Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo …

K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix… - Lancet Oncol, 2019 - core.ac.uk
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled …

K Nakagawa, EB Garon, T Seto, M Nishio… - THE LANCET …, 2019 - research.unipd.it
Background: Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
[PDF] ksyrigos.gr

[PDF][PDF] Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo …

K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix… - 2019 - ksyrigos.gr
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled …

K Nakagawa, EB Garon, T Seto… - The Lancet …, 2019 - okayama.elsevierpure.com
Background: Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
[PDF] academia.edu

[PDF][PDF] Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo …

K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix… - Lancet Oncol, 2019 - academia.edu
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled …

K Nakagawa, EB Garon, T Seto… - The Lancet …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled …

K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix… - The Lancet …, 2019 - Elsevier
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …

[引用][C] Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo …

K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix… - The Lancet …, 2019 - cir.nii.ac.jp
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell
lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | CiNii …
[PDF] kindai.ac.jp

[PDF][PDF] Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo …

K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix… - 2019 - med.kindai.ac.jp
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …